C & O Pharmaceutical Technology (Holdings) announced today that its net profit increased 40% to HK$41 million ($7.3 million) for the three months ended 31 March 2010 (3QFY10).

During the quarter, the group’s revenue grew 17% to HK$166 million as a result of higher sales recorded for both Exclusive and C&O Branded product segments.

Sales of Exclusive products increased 21% to HK$113 million while sales of C&O Branded products rose 12% to HK$49 million year-on-year.

C & O Pharmaceutical Technology says the group’s balance sheet remains strong, with total cash (including fixed deposits held at banks and cash and cash equivalents) of HK$276 million as at 31 March 2010.